AbbVie Inc.
METHODS OF ADMINISTERING ELAGOLIX
Last updated:
Abstract:
The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.
Status:
Application
Type:
Utility
Filling date:
8 May 2020
Issue date:
27 Aug 2020